BGBIO — Bergenbio ASA Income Statement
0.000.00%
- NOK34.68bn
- NOK34.57bn
- NOK0.35m
Annual income statement for Bergenbio ASA, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.9 | 0.601 | 0.774 | 0.389 | 0.354 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 213 | 262 | 315 | 306 | 192 |
Operating Profit | -204 | -261 | -314 | -306 | -192 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -199 | -257 | -309 | -302 | -190 |
Provision for Income Taxes | |||||
Net Income After Taxes | -199 | -257 | -309 | -302 | -190 |
Net Income Before Extraordinary Items | |||||
Net Income | -199 | -257 | -309 | -302 | -190 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -199 | -257 | -309 | -302 | -190 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.387 | -0.394 | -0.404 | -0.391 | -0.133 |
Dividends per Share |